SigmaPharm Laboratories, LLC – Trademark Portfolio
Entity Type: 16
SigmaPharm Laboratories, LLC holds 17 U.S. trademarks filed with the United States Patent and Trademark Office (USPTO), with a strong focus on Class 5 (Pharmaceuticals) — 12 filings in this category. The portfolio also extends into Class 42 (Computer & Scientific) across 2 Nice Classification classes. Currently, 7 trademarks are registered and 1 is pending. Notable registered marks include SIGMAPHARM and SIGMAPHARM LABORATORIES. The owner is based in Bensalem, PA.
3375 Progress Drive
Bensalem, PA 19020
Showing of trademarks Trademarks
Trademark Classifications
SigmaPharm Laboratories, LLC's trademark portfolio spans 2 Nice Classification classes, reflecting the scope of goods and services protected under their brand portfolio.
Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes
Scientific and technological services; industrial analysis and research services
Frequently Asked Questions
How many trademarks does SigmaPharm Laboratories, LLC have?
SigmaPharm Laboratories, LLC has 17 U.S. trademarks filed with the USPTO. Of these, 7 registered, 1 pending, 8 abandoned, 1 cancelled.
What trademark classes does SigmaPharm Laboratories, LLC file in?
SigmaPharm Laboratories, LLC files trademarks across 2 Nice Classification classes. The most active classes are Class 5 (Pharmaceuticals), Class 42 (Computer & Scientific). Class 5 covers pharmaceutical and veterinary preparations; sanitary preparations for medical purposes.
What are SigmaPharm Laboratories, LLC's most well-known trademarks?
SigmaPharm Laboratories, LLC's registered trademark portfolio includes well-known marks such as SIGMAPHARM and SIGMAPHARM LABORATORIES. These are among 7 currently registered trademarks in the portfolio.
What is SigmaPharm Laboratories, LLC's trademark registration success rate?
SigmaPharm Laboratories, LLC has a 44% trademark registration rate, with 7 out of 16 resolved applications resulting in successful registration. Currently, 1 application is pending review.